36 participants
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-11-01
Conditions
- HIV Infections
Interventions
- BIOLOGICAL
- DRUG
No Results Yet